SEM1
ENSG00000127922
Target class
Unclassified protein
Chromosome
7
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- SEM1
- Gene name
- SEM1 26S proteasome subunit
- Gene symbol
- SEM1
- Protein name
- 26S proteasome complex subunit SEM1 (26S proteasome complex subunit DSS1) (Deleted in split hand/split foot protein 1) (Split hand/foot deleted protein 1) (Split hand/foot malformation type 1 protein)
- DSS1
- Shfdg1
- ECD
- SHSF1
- FLJ42280
- PSMD15
- SHFD1
- SHFM1
- C7orf76
- Gene biotype
- Protein coding
- Gene family
- Proteasome|Transcription and export complex 2
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 22.52
- Tissue specificity (Gini)
- 0.214
- Tissue specificity (tau)
- 0.494
- KEGG gene identifiers
- hsa:7979
- Protein interaction confidence
- 0.856152
- Protein interaction partners
- 46
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 53 more, listed on the interactive page.
- End position
- 96709891
- Start position
- 96481626
- Chromosome
- 7
- Strand
- Reverse
- Nucleus .
- Cytosol
Publication evidence
- PubMed 26833090
- Tissue specificity (tau)
- 0.49411
- Expression inequality (Gini)
- 0.214044
Expression in transcripts per million
- Testis
- 22.52
- Cells - EBV-transformed lymphocytes
- 22.13
- Cells - Cultured fibroblasts
- 22
- Ovary
- 19.47
- Cervix - Endocervix
- 17.02
Expression in transcripts per million
- Testis22.52
- Cells - EBV-transformed lymphocytes22.13
- Cells - Cultured fibroblasts22
- Ovary19.47
- Cervix - Endocervix17.02
- Uterus16.9
- Cervix - Ectocervix16.64
- Artery - Tibial16.45
- Vagina15.93
- Esophagus - Mucosa14.55
- Artery - Aorta14.53
- Nerve - Tibial14.42
- Fallopian Tube14.07
- Prostate13.99
- Skin - Sun Exposed (Lower leg)13.85
- Artery - Coronary13.67
- Colon - Sigmoid13.61
- Skin - Not Sun Exposed (Suprapubic)13.58
- Thyroid13.53
- Adipose - Subcutaneous13.51
- Adrenal Gland13.21
- Pituitary13.19
- Breast - Mammary Tissue13.19
- Esophagus - Gastroesophageal Junction12.5
- Esophagus - Muscularis12.19
And 29 more, listed on the interactive page.
Related records
Trials (789)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (5)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor